Company Overview
Denali Therapeutics Inc. operates as a biopharmaceutical company dedicated to discovering and developing therapeutics designed to treat neurodegenerative and lysosomal storage diseases. The company's portfolio also includes the Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program targeting peripheral inflammatory diseases and the BIIB122/DNL151 LRRK2 inhibitor program. This entity functions within the healthcare sector, specifically the biotechnology industry, which focuses on the application of biological processes to develop medical products and therapies. The company maintains a market capitalization of $3.13B and employs 503 individuals across its operations. These financial and operational figures indicate that Denali Therapeutics holds a substantial market presence within the specialized biotechnology landscape, supported by a significant workforce and a valuation that reflects investor confidence in its pipeline despite current profitability challenges.
Financial Health
The company reports a Net Income (TTM) of $-512,540,000 and an EBITDA of $-540,529,984, while Revenue (TTM) is listed as N/A. The absence of reported revenue alongside negative net income and EBITDA reveals a cost structure heavily dominated by research and development expenses rather than current product sales, which is typical for early-stage biopharmaceutical firms. The Free Cash Flow stands at $-244,188,752, indicating that the company is currently burning cash to fund its operations and pipeline development rather than generating liquidity from core business activities. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, which indicates that the company has not yet achieved profitability or that revenue data is insufficient to calculate standard margins, reflecting the pre-commercialization nature of its current portfolio. The company holds $867.88M in cash against $42.29M in debt, resulting in a Debt to Equity ratio of 4.17, which suggests a balance sheet that is currently leveraged but supported by a robust cash reserve relative to its short-term obligations. The Current Ratio is 9.16, a figure that indicates exceptional short-term liquidity, suggesting the company possesses more than nine times the current assets necessary to cover its current liabilities. Return on Equity is -45.7% and Return on Assets is -27.6%, metrics that reveal that management has not yet generated positive returns on the capital invested or the assets accumulated, a common characteristic for biotechnology firms in the discovery and development phases.
Valuation Assessment
The P/E Ratio (TTM) is N/A due to the lack of earnings, while the Forward P/E is -7.96. The discrepancy between a trailing P/E that cannot be calculated and a negative forward P/E implies that the market is pricing the stock based on future expectations of earnings recovery or pipeline success rather than historical profitability. The Price to Book ratio is 3.04, which indicates that the market is valuing the company at a significant premium over its tangible book value, reflecting the high potential value of its intellectual property and drug candidates. The Price to Sales ratio is N/A and the EV/EBITDA is -4.27, alternative valuation metrics that suggest the market is currently valuing the firm based on asset strength and cash position rather than earnings generation or sales multiples. The stock has traded between a 52-Week High of $23.77 and a 52-Week Low of $10.57. Without a specific current price provided in the source data, the valuation range suggests a wide band of volatility where the stock has fluctuated by over 120% in the past year. The Beta is 1.08, which explains that the stock's price volatility is slightly higher than that of the broader market, meaning it tends to move more aggressively than the general market index during periods of price swings.
Growth & Income
Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, indicating that the company has not yet reached a stage of consistent commercial growth where year-over-year metrics can be reliably calculated or reported. Since the company is not currently generating revenue or profits, there is no earnings growth rate to compare against revenue growth, and the focus remains entirely on pipeline progression rather than top-line expansion. The Dividend Yield is N/A and the Payout Ratio is 0.0%, confirming that the company does not distribute dividends to shareholders. This lack of dividend payments is consistent with a reinvestment strategy where the company retains all available capital, including its $867.88M cash balance, to fund ongoing research and development efforts rather than paying out income to investors. The overall growth and income profile for Denali Therapeutics Inc. is characterized by a complete absence of current income generation, with all financial analysis focused on asset valuation, cash reserves, and the potential future value of its therapeutic pipeline rather than historical growth rates or dividend yields.